garcinielliptone FC: from seeds of Platonia insignis; structure in first source
Flora | Rank | Flora Definition | Family | Family Definition |
---|---|---|---|---|
Platonia | genus | [no description available] | Clusiaceae | The mangosteen plant family (sometimes classified as Guttiferae; also known as Hypericaceae) of the order THEALES, subclass Dilleniidae, class Magnoliopsida. It includes trees and shrubs with resinous, sticky sap, usually with broad-ended, oblong, leathery leaves with a strong, central vein, flowers with many stamens.[MeSH] |
ID Source | ID |
---|---|
PubMed CID | 24850574 |
MeSH ID | M0575125 |
Synonym |
---|
garcinielliptone fc |
(1r,5r,7s)-1-(3,4-dihydroxybenzoyl)-4-hydroxy-8,8-dimethyl-3,5-bis(3-methylbut-2-enyl)-7-[(2s)-5-methyl-2-prop-1-en-2-ylhex-5-enyl]bicyclo[3.3.1]non-3-ene-2,9-dione |
Garcinielliptone FC (GFC) is a polyprenylated benzophenone isolated from the hexanic extract of Platonia insignis seeds. It has proven to have antiepileptic, cytotoxic and antioxidant activity.
Excerpt | Reference | Relevance |
---|---|---|
"Garcinielliptone FC did not increase micronucleus frequency in bone marrow." | ( A 28-day Sub-acute Genotoxic and Behavioural Assessment of Garcinielliptone FC. Coelho, VR; Corrêa, DS; Dallegrave, E; de Souza, LP; Ferraz, ABF; Leal, MB; Pereira, P; Pfluger, P; Picada, JN; Prado, LS; Regner, GG; Rossato, RR; Valle, MTC; Vieira, CG, 2018) | 1.45 |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 9 (75.00) | 24.3611 |
2020's | 3 (25.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.01) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 12 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |